Expert Insights

How to prevent muscle loss on Mounjaro

Sword Editorial Team

Footnotes

1

Neeland IJ, Linge J, Birkenfeld A, et al. Changes in lean body mass with glucagon-like peptide-1–based therapies and mitigation strategies. Diabetes Obes Metab. 2024;24(Suppl 4):16-27. https://pubmed.ncbi.nlm.nih.gov/38937282/

2

Wilding JPH, Batterham RL, Calanna S, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/

3

Mass General Brigham. Preserving lean mass in GLP-1 users. 2024.

4

Sword Health. Move Book of Business data. 2023.

5

Johnson B, Milstead M, Thomas O, et al. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonists: a cross-sectional study. Front Nutr. 2025. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1566498/full

Portugal 2020Norte 2020European UnionPlano de Recuperação e ResiliênciaRepública PortuguesaNext Generation EU